Go to Article
Excerpt from www.madinamerica.com
From Maryanne Demasi Reports: “In 2018, a group of physicians and researchers petitioned the FDA to ‘immediately require the addition of boxed warnings and precautions [about Post-SSRI Sexual Dysfunction (PSSD)]’ on the drug labels and asked that ‘Dear Doctor’ letters be issued to prescribers to warn of such risks.
‘Even though the risk of PSSD may be rare, the condition is severe enough to sway someone’s decision to take the drug,’ said [psychiatrist Josef] Witt-Doerring.
‘They might have mild depression and decide they’ll do talk therapy instead of taking the small risk of permanent sexual dysfunction. It’s important for people to have informed consent,’ he added.
About The Author
